Table of Contents
Thrombosis
Volume 2011 (2011), Article ID 530183, 10 pages
http://dx.doi.org/10.1155/2011/530183
Review Article

Clinical Use of the Low-Molecular-Weight Heparins in Cancer Patients: Focus on the Improved Patient Outcomes

1Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison WI 53792, USA
2University of Wisconsin Paul Carbone Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
3Departments of Medicine, Human Oncology, and Neurology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA

Received 2 November 2010; Accepted 17 February 2011

Academic Editor: Ted Wun

Copyright © 2011 Bo H. Chao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. A. Shlebak and D. B. Smith, “Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy,” Cancer Chemotherapy and Pharmacology, vol. 39, no. 5, pp. 462–466, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Y. Y. Lee and M. N. Levine, “Venous thromboembolism and cancer: risks and outcomes,” Circulation, vol. 107, no. 23, pp. I17–I21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Goldenberg, S. R. Kahn, and S. Solymoss, “Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4194–4199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. G. Hamilton, R. D. Hull, and G. F. Pineo, “Venous thromboembolism in neurosurgery and neurology patients: a review,” Neurosurgery, vol. 34, no. 2, pp. 280–296, 1994. View at Google Scholar · View at Scopus
  5. T. J. Iberti, M. Miller, A. Abalos et al., “Abnormal coagulation profile in brain tumor patients during surgery,” Neurosurgery, vol. 34, no. 3, pp. 389–395, 1994. View at Google Scholar · View at Scopus
  6. P. Millac, “Platelet stickness in patients with intracranial tumours,” British Medical Journal, vol. 4, no. 570, pp. 25–26, 1967. View at Google Scholar · View at Scopus
  7. M. Nathanson and J. P. Savitsky, “Platelet adhesive index studies in multiple sclerosis and other neurological disorders,” Bulletin of the New York Academy of Medicine, vol. 28, pp. 462–468, 1952. View at Google Scholar
  8. S. Sallah, A. Husain, V. Sigounas et al., “Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy,” Clinical Cancer Research, vol. 10, no. 21, pp. 7238–7243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. G. F. V. Tempelhoff, M. Dietrich, G. Hommel, and L. Heilmann, “Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer,” Journal of Clinical Oncology, vol. 14, no. 9, pp. 2560–2568, 1996. View at Google Scholar · View at Scopus
  10. G. F. Von Tempelhoff, M. Dietrich, F. Niemann, D. Schneider, G. Hommel, and L. Heilmann, “Blood coagulation and thrombosis in patients with ovarian malignancy,” Thrombosis and Haemostasis, vol. 77, no. 3, pp. 456–461, 1997. View at Google Scholar · View at Scopus
  11. J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W. M. O'Fallon, and L. J. Melton, “Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study,” Archives of Internal Medicine, vol. 160, no. 6, pp. 809–815, 2000. View at Google Scholar · View at Scopus
  12. J. W. Blom, C. J. M. Doggen, S. Osanto, and F. R. Rosendaal, “Malignancies, prothrombotic mutations, and the risk of venous thrombosis,” Journal of the American Medical Association, vol. 293, no. 6, pp. 715–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. P. D. Stein, A. Beemath, F. A. Meyers, E. Skaf, J. Sanchez, and R. E. Olson, “Incidence of venous thromboembolism in patients hospitalized with cancer,” American Journal of Medicine, vol. 119, no. 1, pp. 60–68, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, “Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients,” Cancer, vol. 110, no. 10, pp. 2339–2346, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. H. K. Chew, T. Wun, D. Harvey, H. Zhou, and R. H. White, “Incidence of venous thromboembolism and its effect on survival among patients with common cancers,” Archives of Internal Medicine, vol. 166, no. 4, pp. 458–464, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Levitan, A. Dowlati, S. C. Remick et al., “Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data,” Medicine, vol. 78, no. 5, pp. 285–291, 1999. View at Publisher · View at Google Scholar
  17. J. W. Blom, J. P. M. Vanderschoot, M. J. Oostindiër, S. Osanto, F. J. M. Van Der Meer, and F. R. Rosendaal, “Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study,” Journal of Thrombosis and Haemostasis, vol. 4, no. 3, pp. 529–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Khorana and G. C. Connolly, “Assessing risk of venous thromboembolism in the patient with cancer,” Journal of Clinical Oncology, vol. 27, no. 29, pp. 4839–4847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, “Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy,” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 632–634, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. N. Levine, M. Gent, J. Hirsch et al., “The thombogenic effect of anticancer drug therapy in women with Stage II breast cancer,” New England Journal of Medicine, vol. 318, no. 7, pp. 404–407, 1988. View at Google Scholar · View at Scopus
  21. H. T. Sørensen, L. Mellemkjær, J. H. Olsen, and J. A. Baron, “Prognosis of cancers associated with venous thromboembolism,” New England Journal of Medicine, vol. 343, no. 25, pp. 1846–1850, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Falanga and M. Marchetti, “Venous thromboembolism in the hematologic malignancies,” Journal of Clinical Oncology, vol. 27, no. 29, pp. 4848–4857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Mandalà, M. Reni, S. Cascinu et al., “Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients,” Annals of Oncology, vol. 18, no. 10, pp. 1660–1665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. A. Brandes, E. Scelzi, G. Salmistraro et al., “Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study,” European Journal of Cancer, vol. 33, no. 10, pp. 1592–1596, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Osman, R. Comenzo, and S. V. Rajkumar, “Deep venous thrombosis and thalidomide therapy for multiple myeloma,” New England Journal of Medicine, vol. 344, no. 25, pp. 1951–1952, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp, “Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Knight, R. J. DeLap, and J. B. Zeldis, “Lenalidomide and venous thrombosis in multiple myeloma,” New England Journal of Medicine, vol. 354, no. 19, pp. 2079–2080, 2006. View at Google Scholar · View at Scopus
  28. J. A. Zonder, B. Barlogie, B. G. M. Durie, J. McCoy, J. Crowley, and M. A. Hussein, “Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis,” Blood, vol. 108, no. 1, p. 403, 2006. View at Publisher · View at Google Scholar
  29. A. K. Kakkar and R. C. N. Williamson, “Prevention of venous thromboembolism in cancer using low-molecular-weight heparins,” Haemostasis, vol. 27, supplement 1, pp. 32–37, 1997. View at Google Scholar · View at Scopus
  30. J. L. Ambrus, C. M. Ambrus, I. B. Mink, and J. W. Pickren, “Causes of death in cancer patients,” Journal of Medicine, vol. 6, no. 1, pp. 61–64, 1975. View at Google Scholar · View at Scopus
  31. V. Bobek, M. Boubelík, J. Kovarik, and O. Taltynov, “Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine,” Neoplasma, vol. 50, no. 2, pp. 148–151, 2003. View at Google Scholar · View at Scopus
  32. V. Bobek and J. Kovarik, “Antitumor and antimetastatic effect of warfarin and heparins,” Biomedicine and Pharmacotherapy, vol. 58, no. 4, pp. 213–219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Hejna, M. Raderer, and C. C. Zielinski, “Inhibition of metastases by anticoagulants,” Journal of the National Cancer Institute, vol. 91, no. 1, pp. 22–36, 1999. View at Google Scholar · View at Scopus
  34. N. M. Kuderer, T. L. Ortel, and C. W. Francis, “Impact of venous thromboembolism and anticoagulation on cancer and cancer survival,” Journal of Clinical Oncology, vol. 27, no. 29, pp. 4902–4911, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. E. Lee, L. A. Rogers, J. M. Longcroft, and R. E. Jeffery, “Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid,” Clinical and Experimental Metastasis, vol. 8, no. 2, pp. 165–171, 1990. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Kyo Lee, B. Choi, R. A. Sobel, E. A. Chiocca, and R. L. Martuza, “Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone,” Journal of Neurosurgery, vol. 73, no. 3, pp. 429–435, 1990. View at Google Scholar · View at Scopus
  37. R. J. Ludwig, B. Boehme, M. Podda et al., “Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis,” Cancer Research, vol. 64, no. 8, pp. 2743–2750, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Maat and P. Hilgard, “Anticoagulants and experimental metastases—evaluation of antimetastatic effects in different model systems,” Journal of Cancer Research and Clinical Oncology, vol. 101, no. 3, pp. 275–283, 1981. View at Google Scholar · View at Scopus
  39. T. Sciumbata, P. Caretto, P. Pirovano et al., “Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival,” Invasion and Metastasis, vol. 16, no. 3, pp. 132–143, 1996. View at Google Scholar · View at Scopus
  40. S. M. Smorenburg and C. J. F. Van Noorden, “The complex effects of heparins on cancer progression and metastasis in experimental studies,” Pharmacological Reviews, vol. 53, no. 1, pp. 93–105, 2001. View at Google Scholar · View at Scopus
  41. S. M. Smorenburg, R. Vink, M. T. Lintelo et al., “In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis,” Clinical and Experimental Metastasis, vol. 17, no. 5, pp. 451–456, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. Stevenson, S. H. Choi, and A. Varki, “Differential metastasis inhibition by clinically relevant levels of heparins—correlation with selectin inhibition, not antithrombotic activity,” Clinical Cancer Research, vol. 11, no. 19, pp. 7003–7011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. E. A. Johnson, T. B. L. Kirkwood, Y. Stirling et al., “Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection,” Thrombosis and Haemostasis, vol. 35, no. 3, pp. 586–591, 1976. View at Google Scholar · View at Scopus
  44. B. Boneu, C. Caranobe, Y. Cadroy et al., “Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit,” Seminars in Thrombosis and Hemostasis, vol. 14, no. 1, pp. 18–27, 1988. View at Google Scholar · View at Scopus
  45. M. Palm and C. Mattsson, “Pharmacokinetics of heparin and low molecular weight heparin fragment (fragmin) in rabbits with impaired renal or metabolic clearance,” Thrombosis and Haemostasis, vol. 58, no. 3, pp. 932–935, 1987. View at Google Scholar · View at Scopus
  46. H. L. Casele, S. A. Laifer, D. A. Woelkers, and R. Venkataramanan, “Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy,” American Journal of Obstetrics and Gynecology, vol. 181, no. 5, pp. 1113–1117, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Abbate, A. M. Gori, A. Farsi, M. Attanasio, and G. Pepe, “Monitoring of low-molecular-weight heparins in cardiovascular disease,” American Journal of Cardiology, vol. 82, pp. 33L–36L, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Boneu, “Low molecular weight heparin therapy: is monitoring needed?” Thrombosis and Haemostasis, vol. 72, no. 3, pp. 330–334, 1994. View at Google Scholar · View at Scopus
  49. S. R. Deitcher, C. M. Kessler, G. Merli, J. R. Rigas, R. M. Lyons, and J. Fareed, “Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period,” Clinical and Applied Thrombosis/Hemostasis, vol. 12, no. 4, pp. 389–396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Meyer, Z. Marjanovic, J. Valcke et al., “Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study,” Archives of Internal Medicine, vol. 162, no. 15, pp. 1729–1735, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. R. D. Hull, G. F. Pineo, R. F. Brant et al., “Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer,” American Journal of Medicine, vol. 119, no. 12, pp. 1062–1072, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Agnelli, G. Gussoni, C. Bianchini et al., “Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study,” The Lancet Oncology, vol. 10, no. 10, pp. 943–949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Y. Y. Lee, M. N. Levine, R. I. Baker et al., “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer,” New England Journal of Medicine, vol. 349, no. 2, pp. 146–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. C. J. van Dongen, A. G. van den Belt, M. H. Prins, and A. W. Lensing, “Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD001100, 2004. View at Google Scholar · View at Scopus
  55. R. Brisman and J. Mendell, “Thromboembolism and brain tumors,” Journal of Neurosurgery, vol. 38, no. 3, pp. 337–338, 1973. View at Google Scholar · View at Scopus
  56. M. C. Kayser Gatchalian and K. Kayser, “Thrombosis and intracranial tumors,” Journal of Neurology, vol. 209, no. 3, pp. 217–224, 1975. View at Google Scholar · View at Scopus
  57. J. R. Perry, J. A. Julian, N. J. Laperriere et al., “PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma,” Journal of Thrombosis and Haemostasis, vol. 8, no. 9, pp. 1959–1965, 2010. View at Publisher · View at Google Scholar
  58. B. H. Chao and H. I. Robins, “The use of low molecular weight heparin in the treatment and prevention of thromboembolic disease in glioma,” in Tumors of the Central Nervous System, M. A. Havat, Ed., Springer, New York, NY, USA, 2010. View at Google Scholar
  59. H. Partsch, B. Kechavarz, A. Mostbeck, H. Kohn, and C. Lipp, “Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin,” Journal of Vascular Surgery, vol. 24, no. 5, pp. 774–782, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Merli, T. E. Spiro, C. G. Olsson et al., “Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment venous thromboembolic disease,” Annals of Internal Medicine, vol. 134, no. 3, pp. 191–202, 2001. View at Google Scholar · View at Scopus
  61. B. A. Duplaga, C. W. Rivers, and E. Nutescu, “Dosing and monitoring of low-molecular-weight heparins in special populations,” Pharmacotherapy, vol. 21, no. 2, pp. 218–234, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz, “Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, pp. 141S–159S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. H. I. Robins, A. O'Neill, M. Gilbert et al., “Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 2, pp. 227–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. H. R. Büller, B. L. Davidson, H. Decousus et al., “Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vienous thrombosis: a randomized trial,” Annals of Internal Medicine, vol. 140, no. 11, pp. 867–873, 2004. View at Google Scholar · View at Scopus
  65. A. Y. Y. Lee, “Anticoagulation in the treatment of established venous thromboembolism in patients with cancer,” Journal of Clinical Oncology, vol. 27, no. 29, pp. 4895–4901, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. Investigators PdRdEPpIC, “Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study,” Circulation, vol. 112, no. 3, pp. 416–422, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Sallah, J. Y. Wan, and N. P. Nguyen, “Venous thrombosis in patients with solid tumors: determination of frequency and characteristics,” Thrombosis and Haemostasis, vol. 87, no. 4, pp. 575–579, 2002. View at Google Scholar · View at Scopus
  68. A. T. Cohen, B. L. Davidson, A. S. Gallus et al., “Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial,” British Medical Journal, vol. 332, no. 7537, pp. 325–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Leizorovicz, A. T. Cohen, A. G. G. Turpie, C. G. Olsson, P. T. Vaitkus, and S. Z. Goldhaber, “Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients,” Circulation, vol. 110, no. 7, pp. 874–879, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. M. M. Samama, A. T. Cohen, J.-Y. Darmon et al., “A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients,” New England Journal of Medicine, vol. 341, no. 11, pp. 793–800, 1999. View at Publisher · View at Google Scholar
  71. R. Alikhan, A. T. Cohen, S. Combe et al., “Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study,” Archives of Internal Medicine, vol. 164, no. 9, pp. 963–968, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. R. H. White, H. Zhou, and P. S. Romano, “Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures,” Thrombosis and Haemostasis, vol. 90, no. 3, pp. 446–455, 2003. View at Google Scholar · View at Scopus
  73. D. Bergqvist, G. Agnelli, A. T. Cohen et al., “Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer,” New England Journal of Medicine, vol. 346, no. 13, pp. 975–980, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Haas, A. Kakkar, and B. Kemkes-Matthes, “Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: results of the TOPIC studies,” Journal of Thrombosis and Haemostasis, vol. 3, article OR059, 2005. View at Google Scholar
  75. H. Riess, U. Pelzer, G. Deutschinoff et al., “A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients with advanced pancreatic cancer: results of the CONKO 004 trial,” Journal of Clinical Oncology, vol. 27, article LBA4506, 2009. View at Google Scholar
  76. A. Maraveyas, J. Waters, R. Roy et al., “Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study),” European Journal of Cancer, Supplement, vol. 7, article 362, 2009. View at Google Scholar
  77. M. T. Nurmohamed, A. M. Van Riel, C. M. A. Henkens et al., “Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery,” Thrombosis and Haemostasis, vol. 75, no. 2, pp. 233–238, 1996. View at Google Scholar · View at Scopus
  78. G. Agnelli, F. Piovella, P. Buoncristiani et al., “Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery,” New England Journal of Medicine, vol. 339, no. 2, pp. 80–85, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. L. D. Dickinson, L. D. Miller, C. P. Patel, and S. K. Gupta, “Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors,” Neurosurgery, vol. 43, no. 5, pp. 1074–1079, 1998. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Conclusive results of a randomized phase III trial by the EROTC Brain and RT groups and NICIC Clinical Trails Group. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme,” Proceedings of the American Society of Clinical Oncology, vol. 23, abstract 2, 2004. View at Google Scholar
  81. L. V. M. Rao, “Tissue factor as a tumor procoagulant,” Cancer and Metastasis Reviews, vol. 11, no. 3-4, pp. 249–266, 1992. View at Publisher · View at Google Scholar · View at Scopus
  82. P. M. Mannucci, “Markers of hypercoagulability in cancer patients,” Haemostasis, vol. 27, supplement 1, pp. 25–31, 1997. View at Google Scholar · View at Scopus
  83. A. I. Schafer, “The hypercoagulable states,” Annals of Internal Medicine, vol. 102, no. 6, pp. 814–828, 1985. View at Google Scholar · View at Scopus
  84. V. A. Drill, “Oral contraceptives and thromboembolic disease,” Journal of the American Medical Association, vol. 221, no. 6, pp. 602–603, 1972. View at Publisher · View at Google Scholar · View at Scopus
  85. F. R. Rickles, W. W. Hancock, R. L. Edwards, and L. R. Zacharski, “Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment,” Seminars in Thrombosis and Hemostasis, vol. 14, no. 1, pp. 88–94, 1988. View at Google Scholar · View at Scopus
  86. P. Prandoni, A. W. A. Lensing, H. R. Buller et al., “Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis,” Lancet, vol. 339, no. 8791, pp. 441–445, 1992. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Monreal, J. Fernandez-Llamazares, J. Perandreu, A. Urrutia, J. C. Sahuquillo, and E. Contel, “Occult cancer in patients with venous thromboembolism: which patients, which cancers,” Thrombosis and Haemostasis, vol. 78, no. 5, pp. 1316–1318, 1997. View at Google Scholar · View at Scopus
  88. J. Contrino, G. Hair, D. L. Kreutzer, and F. R. Rickles, “In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease,” Nature Medicine, vol. 2, no. 2, pp. 209–215, 1996. View at Publisher · View at Google Scholar · View at Scopus
  89. V. Costantini and L. R. Zacharski, “The role of fibrin in tumor metastasis,” Cancer and Metastasis Reviews, vol. 11, no. 3-4, pp. 283–290, 1992. View at Publisher · View at Google Scholar · View at Scopus
  90. H. F. Dvorak, D. R. Senger, and A. M. Dvorak, “Fibrin as a component of the tumor stroma: origins and biological significance,” Cancer and Metastasis Reviews, vol. 2, no. 1, pp. 41–73, 1983. View at Publisher · View at Google Scholar · View at Scopus
  91. L. R. Zacharski, W. G. Henderson, and F. R. Rickles, “Rationale and experimental design for the VA cooperative study of anticoagulation (warfarin) in the treatment of cancer,” Cancer, vol. 44, no. 2, pp. 732–741, 1979. View at Google Scholar · View at Scopus
  92. J. Folkman, R. Langer, and R. J. Linhardt, “Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone,” Science, vol. 221, no. 4612, pp. 719–725, 1983. View at Google Scholar · View at Scopus
  93. K. Norrby, “Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically,” Haemostasis, vol. 23, supplement 1, pp. 141–149, 1993. View at Google Scholar · View at Scopus
  94. M. Bitan, M. Mohsen, E. Levi et al., “Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin,” Israel Journal of Medical Sciences, vol. 31, no. 2-3, pp. 106–118, 1995. View at Google Scholar · View at Scopus
  95. J. J. Castellot Jr., J. Choay, and J. C. Lormeau, “Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group,” Journal of Cell Biology, vol. 102, no. 5, pp. 1979–1984, 1986. View at Google Scholar
  96. A. Collen, S. M. Smorenburg, E. Peters et al., “Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in Vitro,” Cancer Research, vol. 60, no. 21, pp. 6196–6200, 2000. View at Google Scholar · View at Scopus
  97. L. R. Zacharski, W. G. Henderson, and F. R. Rickles, “Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75,” Cancer, vol. 53, no. 10, pp. 2046–2052, 1984. View at Google Scholar · View at Scopus
  98. A. W. A. Lensing, M. H. Prins, B. L. Davidson, and J. Hirsh, “Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis,” Archives of Internal Medicine, vol. 155, no. 6, pp. 601–607, 1995. View at Publisher · View at Google Scholar · View at Scopus
  99. R. D. Hull, G. E. Raskob, G. F. Pineo et al., “Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis,” New England Journal of Medicine, vol. 326, no. 15, pp. 975–982, 1992. View at Google Scholar · View at Scopus
  100. S. Siragusa, B. Cosmi, F. Piovella, J. Hirsh, and J. S. Ginsberg, “Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis,” American Journal of Medicine, vol. 100, no. 3, pp. 269–277, 1996. View at Publisher · View at Google Scholar · View at Scopus
  101. Study CEM, “A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study,” Journal of Thrombosis and Haemostasis, vol. 65, pp. 251–256, 1991. View at Google Scholar
  102. G. Simonneau, B. Charbonnier, H. Decousus et al., “Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis,” Archives of Internal Medicine, vol. 153, no. 13, pp. 1541–1546, 1993. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Y. Y. Lee, F. R. Rickles, J. A. Julian et al., “Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2123–2129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Altinbas, H. S. Coskun, O. Er et al., “A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer,” Journal of Thrombosis and Haemostasis, vol. 2, no. 8, pp. 1266–1271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. A. K. Kakkar, M. N. Levine, Z. Kadziola et al., “Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS),” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1944–1948, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. C. P. W. Klerk, S. M. Smorenburg, H. M. Otten et al., “The effect of low molecular weight heparin on survival in patients with advanced malignancy,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2130–2135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Sideras, P. L. Schaefer, S. H. Okuno et al., “Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial,” Mayo Clinic Proceedings, vol. 81, no. 6, pp. 758–767, 2006. View at Publisher · View at Google Scholar · View at Scopus